Active Ingredient(s): Ruxolitinib Phosphate
FDA Approved: * September 21, 2021
Pharm Company: * INCYTE CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Opzelura Overview

Ruxolitinib, sold under the brand names Jakafi and Jakavi, is a medication for the treatment of intermediate or high-risk myelofibrosis,[1] a type of myeloproliferative disorder that affects the bone marrow;[5][6] polycythemia vera (PCV), when there has been an inadequate response to or intolerance of hydroxyurea;[1][7] and steroid-refractory acute graft-versus-host disease.[1] It was developed and...

Read more Opzelura Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ruxolitinib

Recent Opzelura Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ruxolitinib Phosphate
  • Cream: 1.5%
  • Tablet: 10mg, 15mg, 20mg, 25mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Opzelura: (1 result)

Sorted by National Drug Code
  • 50881-007 Opzelura 15 mg/g Topical Cream by Incyte Corporation

Other drugs which contain Ruxolitinib Phosphate or a similar ingredient: (2 results)